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Abstract
Clear cell renal cell carcinoma (CCRCC) is a heterogeneous and complex disease that fre-
quently develops distant metastases. Fibroblast activation protein (FAP) is a serine pepti-
dase the expression of which in cancer-associated fibroblasts has been associated with
higher risk of metastases and poor survival. The objective of this study was to evaluate the
role of FAP in metastatic CCRCC (mCCRCC). A series of 59 mCCRCC retrospectively col-
lected was included in the study. Metastases developed either synchronous (n = 14) or
metachronous to renal disease (n = 45). Tumor specimens were obtained from both primary
lesion (n = 59) and metastases (n = 54) and FAP expression was immunohistochemically
analyzed. FAP expression in fibroblasts from primary tumors correlated with FAP expres-
sion in the corresponding metastatic lesions. Also, primary and metastatic FAP expression
was correlated with large tumor diameter (>7cm), high grade (G3/4), high stage (pT3/4),
tumor necrosis and sarcomatoid transformation. The expression of FAP in primary tumors
and in their metastases was associated both with synchronous metastases and also with
metastases to the lymph nodes. FAP expression in the primary tumor was correlated with
worse 10-year overall survival. Immunohistochemical detection of FAP in the stromal tumor
fibroblasts could be a biomarker of early lymph node metastatic status and therefore could
account for the poor prognosis of FAP positive CCRCC.
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Introduction
Renal cancer ranks within the top-ten list of the most frequent malignancies in Western Coun-
tries. Epidemiological data reveal that its incidence has been increasing in Europe and United
States during the last years [1,2]. Clear cell renal cell carcinoma (CCRCC) is the most common
histological subtype, accounting approximately for 75–80% of the cases [3]. CCRCC is fre-
quently resistant to current chemo- and radiotherapy, and the standard treatment is complete
resection of the primary tumor by radical or partial nephrectomy [4].
At the time of diagnosis approximately 25% of the patients display locally advanced or met-
astatic disease and about 33% of organ-confined tumors will develop metastatic disease [5].
Although immunotherapy and other targeted therapies have recently provided promising
results, patients with metastatic CCRCC (mCCRCC) still have a poor prognosis [6]. Therefore,
biomarkers associated with metastatic status in CCRCC are important for early detection and
for the identification of new therapeutic targets [6,7].
Cancer-associated fibroblasts (CAFs) are the most ubiquitous elements of tumor stroma
and are found in numerous types of solid cancers [8]. The cross-talk between neoplastic cells
and CAFs in tumor microenvironment is crucial in CCRCC progression, invasion and metas-
tasis, and in the acquisition of drug resistance [9]. A hallmark of the activation of these CAFs is
the cell surface expression of fibroblast activation protein-α (FAP), a serine peptidase with
multifunctional properties [10]. The overexpression of FAP in CAFs and in tumor cells has
been associated with higher risk of metastases and worse survival in several solid tumors
[9,11].
A recent study has demonstrated that the interaction of renal cancer cell lines with CAFs
stimulates proliferation, survival and migration of tumor cells, thus indicating that these stro-
mal cells play an important role supporting and promoting renal cancer progression [12].
However, FAP expression in renal cell carcinomas has not been previously documented in the
literature. Very recently, we described the expression of this protein in a series of CCRCC, and
demonstrated a correlation between FAP immunostaining in CAFs and poor patient outcome
[13].
For a better understanding of the prognostic implications of this serine peptidase in renal
cancer, we analyzed the immunohistochemical expression of FAP in CAFs both in primary
tumors and in their metastases from a series of CCRCC.
Materials and Methods
The authors declare that all experiments carried out in this study comply with current Spanish
and European Union legal regulations. Samples and data from patients included in this study
were provided by the Basque Biobank for Research-OEHUN (www.biobancovasco.org). All
patients were informed about the potential use for research of their surgically resected tissues,
and accepted this eventuality by signing a specific document approved by the Ethical and Sci-
entific Committees of the Basque Country Public Health System (Osakidetza) (CEIC 2015/
060, CEIC-E PI2015101).
Patients and tissue specimens
59 patients with mCCRCC were included in this retrospective study. Primary tumors and
metastases originated from the same patients and were surgically excised in every case. Clin-
ical and pathological data of the selected samples are summarized in Table 1. Males predom-
inated in the series (45M/14F). Mean age was 59 years. Follow-up data was obtained from
the clinical records and was closed at Dec 31, 2014. At that time, 38 patients (64%) had died
of disease. Mean follow-up was 65 months. Average tumor diameter of primary tumors was
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7.9 cm (range 2-19cm). Twenty-four cases were low-grade (G1-2) and 34 high-grade (G3-
4). At the time of diagnosis 32 cases were organ-confined (pT1/2) and 27 locally advanced
or metastatic (pT3/4). Sarcomatoid changes were detected in 4 cases and tumor necrosis
in 30.
With regard to the metastatic status, 14 cases displayed synchronous metastases at the time
of diagnosis and 45 developed metachronous metastatic disease after renal surgery. Thirty-one
cases metastasized in epithelial organs, 16 in the soft tissues and bones and 12 in lymph nodes.
Primary tumors and metastasis were surgically excised in every case. However, metastatic tis-
sue available for immunohistochemical analysis was limited to 54 cases since the obtained
samples in five cases were very scarce (core biopsies) and exclusively allowed the diagnosis on
hematoxylin-eosin sections. Cases were reviewed by two pathologists (JIL, RG), who assigned
Fuhrman’s grade [14] and 2010 AJCC Staging System [15].
Table 1. Clinical and pathological parameters of CCRCC patients (n = 59).
Patients Average (%)
Age (range) 59 (25–83)
Sex
Male 45 (76%)
Female 14 (24%)
Follow-up (months) 65 (1–240)
Survival
Alive 21 (36%)
Dead of disease 38 (64%)
Primary tumor n
Diameter
 7cm 34 (58%)
> 7cm 25 (42%)
Grouped grade
Low (G1-G2) 24 (41%)
High (G3-G4) 35 (59%)
Grouped pT*
Low (pT1-pT2) 32 (54%)
High (pT3-pT4) 27 (46%)
Sarcomatoid
No 55 (93%)
Yes 4 (7%)
Necrosis
No 29 (49%)
Yes 30 (51%)
Metastases n
Synchronous 14 (24%)
Metachronous 45 (76%)
Location
Lymphatic nodes 12 (20%)
Epithelial tissues 31 (53%)
Soft/bone tissues 16 (27%)
(*) Grouped pT: organ confined (pT1-pT2) vs non organ confined (pT3-pT4) disease
doi:10.1371/journal.pone.0169105.t001
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Immunohistochemistry assay
Immunohistochemistry with carbonic anhydrase IX (Epitomics, ref. code AC-0137RUO, dilu-
tion 1: 100), CK7 (Ventana, ref. code 790–4462, ready to use) and CD117 (Ventana, ref. code
790–2951, ready to use) was performed to confirm the diagnosis of CCRCC only in selected
cases. Tissue microarrays were performed for the evaluation of FAP expression in primary and
metastatic tumors. The presence/absence of FAP (Rabbit polyclonal to Fibroblast Activation
Protein alpha, Abcam, ref. ab53066, dilution 1:70) was evaluated in the stromal fibroblasts
adjacent to neoplastic nests. Immunostainings were performed in automated immunostainers
(EnVision FLEX, Dako Autostainer Plus; Dako, Glostrup, Denmark and BenchMark Ultra,
Ventana Medical Systems, Tucson, AZ, USA) following routine methods. Tris-EDTA was
used for antigen retrieval in all cases. Negative controls were slides not exposed to the primary
antibody, and these were incubated in PBS and then processed under the same conditions as
the test slides. The analysis was performed using a Nikon Eclipse 80i microscope (Tokyo,
Japan).
Western-blot analysis
1 μg of human recombinant FAP protein (CF 3715-SE-010, R&D Systems) was loaded in a
SDS-PAGE gel and transferred onto a PVDF membrane. The band was marked with a rabbit
antibody against FAP (ab53066, 1:500, Abcam). The band was then detected with HRP-conju-
gated goat anti-rabbit antibody (sc-2004; Santa Cruz Biotechnology; 1:1000) and visualized
with ECL substrate (S1 Fig).
Statistical analysis
SPSS1 21.0 software was used for the statistical analysis. Chi-square (χ2) test was used to ana-
lyze the association between categorical FAP expression (negative or positive) and pathological
variables of CCRCCs. Spearman rho test was used to correlate FAP expression in both primary
tumors and metastases, and with patients age and sex. Kaplan-Meier curves and log-rank test
were performed to evaluate 10-year overall survival of the series according to the status of FAP
expression in the primary tumor and in the metastases. Multivariate analysis was used to test
the independent effects of clinical and pathological variables on survival. A stepwise selection
procedure (forward conditional method) with a threshold entry of p = 0.20 and a stay criterion
of p = 0.20 was used to select the optimal predictive model.
Results
Immunohistochemical expression of FAP in tumors
Histologically, FAP expression was evaluated in the fibroblasts of the tumor stroma in both
primary and metastatic tumors (Fig 1). The staining was cytoplasmic and involved exclusively
the stromal fibroblasts adjacent to neoplastic epithelial cells, with a pattern of distribution that
has been previously described [13].
FAP expression according to clinical and pathological variables
FAP expression correlated positively in paired primary tumors and metastases (Spearman rho
test r = 0.51; p = 0.0001). FAP was positive in 36% primary and 44% metastatic lesions. A sta-
tistically significant association was found between FAP expression and pathological parame-
ters of tumor aggressiveness (Tables 2 and 3). Thus, FAP immunostaining was higher in high
grade and high stage primary CCRCCs, and in tumors showing sarcomatoid transformation
and necrosis (Table 2). FAP expression in metastases showed similar correlations with these
Fibroblast Activation Protein in mCCRCC
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variables (with the exception of tumor grade), but also correlated with higher tumor diameter
(Table 3). On the other hand, FAP was not correlated with age and sex (Spearman rho test
p>0.05).
With regard to the temporal presentation of metastases, 14 were synchronous and 45 meta-
chronous. In tumors with synchronous metastases FAP was expressed in 86% of the primaries
and in 83% of the metastases (Table 2). By contrast, FAP was only positive in 20% of the pri-
maries and in 33% of the metastases when they were metachronous (Table 3).
With regard to the metastatic location, 50% of the synchronous metastases were detected in
the lymph nodes, 29% in epithelial organs and 21% in the soft tissues and bones. Conversely,
metachronous metastases appeared mainly in epithelial organs (59%), followed by the soft tis-
sues and bones (28%) and lymph nodes (13%). This different temporal topographic distribu-
tion was statistically significant (Chi-square χ2 test; p = 0.012).
Fig 1. FAP immunohistochemical expression in primary and metastatic CCRCC. Clear cell renal cell carcinoma arranged in nests (A) show FAP-
positive cancer-associated fibroblasts delineating tumor lobes (B). Lymph node metastatic tumor growing more diffusely without recognizable architecture
(C) displays FAP-positive cancer-associated fibroblasts intimately intermingled with tumor cells (D).
doi:10.1371/journal.pone.0169105.g001
Fibroblast Activation Protein in mCCRCC
PLOS ONE | DOI:10.1371/journal.pone.0169105 December 29, 2016 5 / 13
Up to 75% of primary tumors that metastasized into lymph nodes were FAP positive. By
contrast, primary tumors that metastasized into the soft tissues and bones and into epithelial
organs were FAP positive only in 33% and 25%, respectively (Table 2). FAP expression in
metastases showed a similar pattern, being significantly higher in lymph nodes than in epithe-
lial organs (Table 3).
FAP expression according to 10-year overall survival of mCCRCC
patients
Kaplan-Meier survival curves were performed in patients with primary and metastatic
CCRCC and showed that FAP positive immunostaining in primary tumors (Fig 2A) was asso-
ciated with poor survival (log-rank; p = 0.018). However, FAP positivity in metastatic lesions
(Fig 2B) did not appear a prognostic factor (log-rank; p = 0.94). Cox regression multivariate
analysis showed that the temporal presentation of metastases (synchronous vs. metachronous)
was the only independent prognostic variable in this population of mCCRCC (p = 0.0007).
However, if the dominant variable regarding the time from diagnosis to development of meta-
static disease is excluded from the model, FAP positive immunostaining of the primary tumor
(p = 0.0608) and initial metastatic location in lymph nodes (p = 0.139) present as determinant
of prognosis in patients with mCCRCC (Table 4). Other well-admitted clinico-pathological
variables, such as stage, size or grade were not predictors in this series. Tumor necrosis
Table 2. Clinical and pathological variables and FAP expression in primary tumors.
Variables Negative (%) Positive (%) Total (n) P value
Diameter
 7cm 74 26 34 0.088
> 7cm 52 48 25
Grade
Low (G1-G2) 88 12 24 0.002
High (G3-G4) 49 51 35
Grouped pT
Low (pT1-pT2) 81 19 32 0.003
High (pT3-pT4) 44 56 27
Sarcomatoid
No 69 31 55 0.005
Yes 0 100 4
Necrosis
No 86 14 29 0.001
Yes 43 57 30
Metastases
Synchronous 14 86 14 0.0001
Metachronous 80 20 45
Location
Lymph nodes 25 75 12 0.005(a)
Epithelial tissues 77 23 31
Soft/bone tissues 69 31 16
(a) FAP expression was significantly higher in metastatic lesions from lymphatic nodes than from epithelial and soft/bone tissues.
Intergroup differences were evaluated using χ2 test. Statistically significant correlations are highlighted in bold.
doi:10.1371/journal.pone.0169105.t002
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appeared statistically significant in univariate analysis but did not maintain in multivariate
model (Table 4).
Discussion
CCRCC is a heterogeneous and complex neoplasm. Metastatic disease is present at diagnosis
in around 30% of patients and another third of those with early-stage CCRCC at diagnosis will
relapse and progress to metastatic disease after nephrectomy [5,16]. In the context of a meta-
static disease, the importance of classic prognostic factors such as tumor diameter, stage and
histological grade of the primary tumor, decreases considerably [17]. So, the identification of
alterations that may influence tumor behavior and clinical outcome in primary tumors and
metastases is needed to improve the management of these patients [18]. Very recently lymph
node metastases have proved negative impact on the survival of mCCRCC treated with tar-
geted therapies [19]. By contrast, the survival benefit of lymph node dissection in patients with
localized disease and clinically enlarged lymph nodes has not been demonstrated and could
represent overtreatment in the majority of cases. Consequently, lymph node dissection is usu-
ally performed for staging purposes [20].
Cancer development and progression rely not only in neoplastic cells themselves, but also
in their interaction with CAFs in tumor microenvironment [8,9,21], among other factors. FAP
is a marker of activated fibroblasts and its expression is more abundant in tumors with invasive
phenotype that are more likely to metastasize [9]. The relationship between FAP expression
Table 3. Clinical and pathological variables and FAP expression in metastases.
Variables Negative (%) Positive (%) Total (n) P value
Diameter
 7cm 70 30 30 0.017
> 7cm 37 73 24
Grade
Low (G1-G2) 65 35 23 0.22
High (G3-G4) 48 52 31
Grouped pT
Low (pT1-pT2) 72 28 29 0.007
High (pT3-pT4) 36 64 25
Sarcomatoid
No 59 41 51 0.046
Yes 0 100 3
Necrosis
No 78 22 27 0.001
Yes 33 67 27
Metastases
Synchronous 17 83 12 0.002
Metachronous 67 33 42
Location
Lymph nodes 31 69 13 0.021(a)
Epithelial tissues 69 31 29
Soft/bone tissues 50 50 12
(a) FAP expression was significantly higher in metastatic lesions from lymphatic nodes than from epithelial tissues.
Intergroup differences were evaluated using χ2 test. Statistically significant correlations are highlighted in bold.
doi:10.1371/journal.pone.0169105.t003
Fibroblast Activation Protein in mCCRCC
PLOS ONE | DOI:10.1371/journal.pone.0169105 December 29, 2016 7 / 13
and poor clinical outcome has been reported [11]. However, these studies have been per-
formed in primary tumors and information about FAP expression in metastatic lesions is
scarce.
In this study, we analyzed FAP expression in the stroma of both primary (FAPp) and meta-
static (FAPm) lesions of the same mCCRCC patients. As reported very recently in a global
Fig 2. Kaplan-Meier survival curves for FAP expression in primary (A) and metastatic (B) clear cell
renal cell carcinomas. 10-year overall survival showed significant differences between FAP protein positive
and negative cases in primary tumors (log-rank test p<0.05).
doi:10.1371/journal.pone.0169105.g002
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series of CCRCCs [13], FAPp immunostaining significantly correlated with high stage, high
grade and necrotic tumors, and implied worse 10-year overall survival. These findings are
recapitulated in the population of CCRCC with metastases at diagnosis or developing metasta-
sis during follow-up. Furthermore, we have found that there is a correlation between FAP
expression in the stromal fibroblasts in primary tumor and in the metastases; however, the
negative impact of FAP on survival is mainly determined by stromal fibroblasts in the primary
tumor and not in the metastases.
The temporal presentation of metastases is itself an important variable influencing progno-
sis in cancer patients. In renal cancer, synchronous metastases are related with worse survival
than metachronous ones [22]. Also concomitant lung or lymph node metastases were inde-
pendent predictors in patients with CCRCC and bone metastases [23]. In our study, the tem-
poral presentation of metastases also remained as the highest significant variable influencing
the survival of mCCRCC patients. This finding has also been detected by different authors,
although they describe this variable under different names, such as time from initial diagnosis
in mCCRCC patients [24], time to nephrectomy to mCCRCC [25] or time from diagnosis to
metastatic disease [26]. In this series, the expression of both FAPp and FAPm was positive in
more than 80% of synchronous metastases, whereas it was negative in most metachronous
lesions.
On the other hand, synchronous metastases occurred mainly in lymph nodes whereas
metachronous were located in epithelial organs. As previously described in other cancers [11],
Table 4. Univariate and Multivariate analyses to predict overall survival of mCCRCC patients.
UNIVARIATE ANALYSIS
Variable Description Point Estimate 95% Wald Confidence
Limits
P-value Log-rank
Diameter  7cm vs > 7cm 1.18 1.63 0.44 0.61
Grouped grade Low (G1-G2) vs High (G3-G4) 1.19 0.62 2.28 0.59
Grouped pT Low (pT1-pT2) vs High (pT3-pT4) 1.01 0.53 1.93 0.97
Sarcomatoid No/Yes 2.66 0.61 11.63 0.17
Necrosis No/Yes 2.17 1.11 4.25 0.02
Synchronicity Synchronous vs Metachronous 6.29 2.44 16.13 <0.0001
Location Lymph node vs Epithelial tissue 1.78 1.3 0.24 0.39
Lymph node vs soft tissue/bone 1.53 1.67 0.26
Epithelial vs soft tissue/bone 0.86 2.45 0.56
Lymph node vs rest 1.69 1.31 0.26 0.19
FAPp Negative vs positive 2.27 1.12 4.57 0.018
FAPm Negative vs positive 1.03 0.51 2.08 0.94
MULTIVARIATE ANALYSIS
Variable Description Point Estimate 95% Wald Confidence
Limits
P-value Cox
Synchronicity Synchronous vs Metachronous 6.29 2.44 16.13 0.0007
MULTIVARIATE ANALYSIS (Excluding Synchronicity)
Variable Description Point Estimate 95% Wald Confidence
Limits
P-value Cox
FAPp Negative vs positive 1.94 0.79 4.75 0.06
Location Lymph node vs rest 1.9 0.88 4.1 0.14
Stepwise Cox proportional hazards test showed synchronicity between primary tumor and metastases was an independent prognostic variable to predict
overall survival. An alternative model revealed FAPp positivity and metastatic location in lymph nodes also predicted overall survival (although it did not
reach statistical significance). Statistically significant results are highlighted in bold.
doi:10.1371/journal.pone.0169105.t004
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most mCCRCCs metastasizing into the lymph nodes were FAP positive. These results suggest
an early migration of cancer cells from FAP positive primary tumors to lymph nodes, and
could explain, at least in part, both the shorter survival outcome of mCCRCC with lymph
node metastases [19,26] and also the relationship between FAP expression and worse progno-
sis of mCCRCC patients.
An important number of CAFs are present closely associated with carcinoma cells in metas-
tases as a part of the tumor microenvironment [27]. Within the lymph nodes, CAFs share sim-
ilar biomarker profiles than in primary tumors [28]. In our study, FAP was also significantly
expressed in nodal CAFs, suggesting that microenvironments in mCCRCC are similar in pri-
mary tumor and in lymph nodes [27,28].
FAP is a multifunctional protein that regulates tumor growth and invasiveness through
mechanisms that are dependent and independent of its catalytic activity [21,29]. For example,
FAP may form complexes with its homologous enzyme, dipeptidyl-peptidase (DPPIV), facili-
tating ECM degradation and thus promoting cancer cell invasion [21,29]. In addition, both
proteins can also act as adhesion molecules, interacting with integrins and influencing the
intracellular signaling of these proteins [21,30]. DPPIV is also increased in advanced CCRCC
and is associated with poor survival rates in these tumors, which suggests that both FAP and
DPPIV may have complementary roles in renal carcinogenesis [13,31,32].
Epithelial-to-mesenchymal transition (EMT) is a reversible process in which cancer cells
loss their epithelial features and transform into mesenchymal cells, and is a crucial step in the
acquisition of metastatic behavior of tumors [33]. Sarcomatoid transformation, a fact that can
be observed in 8–10% of CCRCCs, represents a good example of neoplastic EMT in renal can-
cer [34]. Patients diagnosed with sarcomatoid CCRCC show a considerable worse prognosis
due to an increased propensity for metastasis [34]. In this study, the immunostaining of FAPp
and FAPm was positive in 100% of sarcomatoid CCRCCs, a finding that supports the idea that
FAP and CAFs could also confer aggressive behavior to renal cancer cells by regulating EMT
[35].
FAP is not found in normal adult tissues and its expression is largely associated to the
stroma of primary and metastatic tumors [11,12,21]. The diagnostic and therapeutic potential
of this distribution pattern is currently under study [9,36–38]. It has been demonstrated very
recently that FAP-targeting fluorescent immunoliposomes can be used for intraoperative
imaging and may improve the accurate and complete resection of tumors and lymph node
metastases [36–37]. Besides, FAP-activated prodrugs have been tested in prostate and breast
cancer with promising results [38–40]. Taking into consideration that CCRCC has only partial
response to targeted therapies and that FAP is expressed in the stroma of more aggressive
CCRCCs, the addition of this serine peptidase to the list of potential therapeutic targets would
open new opportunities for these patients.
Conclusions
1) FAP is expressed in CAFs from primary CCRCCs and their metastases. 2) The expression of
FAP may predict early presentation of CCRCC metastases to lymphatic nodes, 3) FAP is sig-
nificantly associated with tumor aggressiveness and poor outcome of patients with mCCRCC
and 4) The simultaneous expression of FAP in primary and metastatic tumors merits further
investigation.
Supporting Information
S1 Fig. FAPα antibody specificity was tested against human recombinat FAPα protein.
The western blot analysis confirmed the detection of a unique band at the expected 85KDa
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molecular mass when the human recombinant FAP protein was loaded, confirming the speci-
ficity of the antibody against FAP.
(TIF)
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